{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,1,29]],"date-time":"2023-01-29T07:31:01Z","timestamp":1674977461049},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,2,19]],"date-time":"2015-02-19T00:00:00Z","timestamp":1424304000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12933-015-0193-4","type":"journal-article","created":{"date-parts":[[2015,2,18]],"date-time":"2015-02-18T00:47:53Z","timestamp":1424220473000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Design and rationale for the randomised, double-blinded, placebo-controlled Liraglutide to Improve corONary haemodynamics during Exercise streSS (LIONESS) crossover study"],"prefix":"10.1186","volume":"14","author":[{"given":"Aung","family":"Myat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satpal","family":"Arri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepak L","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard J","family":"Gersh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon R","family":"Redwood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael S","family":"Marber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,2,19]]},"reference":[{"key":"193_CR1","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1210\/jcem-24-10-1076","volume":"24","author":"H Elrick","year":"1964","unstructured":"Elrick H, Stimmler L, Hlad CJ, Arai Y. Plasma insulin response to oral and intravenous glucose. J Clin Endocrinol Metab. 1964;24:1076\u201382.","journal-title":"J Clin Endocrinol Metab."},{"key":"193_CR2","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1172\/JCI105685","volume":"46","author":"MJ Perley","year":"1967","unstructured":"Perley MJ, Kipnis DM. Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects. J Clin Invest. 1967;46:1954\u201362.","journal-title":"J Clin Invest."},{"key":"193_CR3","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1210\/jcem-37-5-826","volume":"37","author":"J Dupre","year":"1973","unstructured":"Dupre J, Ross S, Watson D, Brown JC. Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocrinol Metab. 1973;37:826\u20138.","journal-title":"J Clin Endocrinol Metab."},{"key":"193_CR4","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1016\/S0140-6736(87)91194-9","volume":"330","author":"B Kreymann","year":"1987","unstructured":"Kreymann B, Ghatei MA, Williams G, Bloom SR. Glucagon-like peptide-1 7\u201336: a physiological incretin in man. Lancet. 1987;330:1300\u20134.","journal-title":"Lancet."},{"key":"193_CR5","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1210\/er.2011-1052","volume":"33","author":"JR Ussher","year":"2012","unstructured":"Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr Rev. 2012;33:187\u2013215.","journal-title":"Endocr Rev."},{"key":"193_CR6","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1136\/heartjnl-2012-303242","volume":"100","author":"A Myat","year":"2014","unstructured":"Myat A, Redwood S, Gersh B, Yellon D, Marber M. Diabetes, incretin hormones and cardioprotection. Heart. 2014;100:1550\u201361.","journal-title":"Heart."},{"key":"193_CR7","first-page":"912","volume":"76","author":"M Nauck","year":"1993","unstructured":"Nauck M, Bartels E, Orskov C, Ebert R, Creutzfeldt W. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7\u201336) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab. 1993;76:912\u20137.","journal-title":"J Clin Endocrinol Metab."},{"key":"193_CR8","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/BF02427280","volume":"2","author":"M Nauck","year":"1986","unstructured":"Nauck M, St\u00f6ckmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in Type 2 (non-insulin-dependent) diabetes. Diabetologia. 1986;2:46\u201352.","journal-title":"Diabetologia."},{"key":"193_CR9","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1007\/s00125-002-0878-6","volume":"45","author":"T Vilsb\u00f8ll","year":"2002","unstructured":"Vilsb\u00f8ll T, Krarup T, Madsbad S, Holst JJ. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia. 2002;45:1111\u20139.","journal-title":"Diabetologia."},{"key":"193_CR10","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/0167-0115(94)90136-8","volume":"51","author":"D Elahi","year":"1994","unstructured":"Elahi D, McAloon-Dyke M, Fukagawa NK, Meneilly GS, Sclater AL, Minaker KL, et al. The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7\u201337) in normal and diabetic subjects. Regul Pept. 1994;51:63\u201374.","journal-title":"Regul Pept."},{"key":"193_CR11","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1172\/JCI116186","volume":"91","author":"M Nauck","year":"1993","unstructured":"Nauck M, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7\u201336 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest. 1993;91:301\u20137.","journal-title":"J Clin Invest."},{"key":"193_CR12","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/S0140-6736(02)07952-7","volume":"359","author":"M Zander","year":"2002","unstructured":"Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet. 2002;359:824\u201330.","journal-title":"Lancet."},{"key":"193_CR13","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.2337\/diab.45.11.1524","volume":"45","author":"J Rachman","year":"1996","unstructured":"Rachman J, Gribble F, Barrow B, Levy J, Buchanan K, Turner R. Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7\u201336) amide in patients with NIDDM. Diabetes. 1996;45:1524\u201330.","journal-title":"Diabetes."},{"key":"193_CR14","doi-asserted-by":"publisher","first-page":"3768","DOI":"10.1210\/jcem.87.8.8743","volume":"87","author":"J Egan","year":"2002","unstructured":"Egan J, Meneilly G, Habener JF, Elahi D. Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state. J Clin Endocrinol Metab. 2002;87:3768\u201373.","journal-title":"J Clin Endocrinol Metab."},{"key":"193_CR15","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","volume":"225","author":"JJ Holst","year":"2007","unstructured":"Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;225:1409\u201339.","journal-title":"Physiol Rev."},{"key":"193_CR16","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.2337\/diab.44.9.1126","volume":"44","author":"CF Deacon","year":"1995","unstructured":"Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes. 1995;44:1126\u201331.","journal-title":"Diabetes."},{"key":"193_CR17","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","volume":"368","author":"DJ Drucker","year":"2006","unstructured":"Drucker DJ, Nauck M. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696\u2013705.","journal-title":"Lancet."},{"key":"193_CR18","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","volume":"369","author":"BM Scirica","year":"2013","unstructured":"Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. SAVOR-TIMI 53 Steering committee and investigators. saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317\u201326.","journal-title":"N Engl J Med."},{"key":"193_CR19","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","volume":"369","author":"WB White","year":"2013","unstructured":"White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, et al. EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327\u201335.","journal-title":"N Engl J Med."},{"key":"193_CR20","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1161\/CIRCRESAHA.114.301958","volume":"114","author":"JR Ussher","year":"2014","unstructured":"Ussher JR, Drucker DJ. Cardiovascular actions of incretin-based therapies. Circ Res. 2014;114:1788\u2013803.","journal-title":"Circ Res."},{"key":"193_CR21","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1210\/en.2012-2124","volume":"154","author":"C Pyke","year":"2013","unstructured":"Pyke C, Knudsen LB. The glucagon-like peptide-1 receptor\u2013or not? Endocrinology. 2013;154:4\u20138.","journal-title":"Endocrinology."},{"key":"193_CR22","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/nm.3128","volume":"19","author":"M Kim","year":"2013","unstructured":"Kim M, Platt MJ, Shibasaki T, Quaggin SE, Backx PH, Seino S, et al. GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat Med. 2013;19:567\u201375.","journal-title":"Nat Med."},{"key":"193_CR23","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.2337\/db13-1440","volume":"63","author":"P Richards","year":"2014","unstructured":"Richards P, Parker H, Adriaenssens A, Hodgson J, Cork S, Trapp S, et al. Identification and characterisation of glucagon-like peptide-1 receptor expressing cells using a new transgenic mouse model. Diabetes. 2014;63:1224\u201333.","journal-title":"Diabetes."},{"key":"193_CR24","doi-asserted-by":"publisher","first-page":"146","DOI":"10.2337\/diabetes.54.1.146","volume":"54","author":"AK Bose","year":"2005","unstructured":"Bose AK, Mm M, Carr RD, Cl B, Yellon DM. Glucagon-like peptide 1 can directly protect the heart against ischemia\/reperfusion injury. Diabetes. 2005;54:146\u201351.","journal-title":"Diabetes."},{"key":"193_CR25","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1161\/CIRCHEARTFAILURE.108.766402","volume":"1","author":"I Poornima","year":"2008","unstructured":"Poornima I, Brown SB, Bhashyam S, Parikh P, Bolukoglu H, Shannon RP. Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat. Circ Heart Fail. 2008;1:153\u201360.","journal-title":"Circ Heart Fail."},{"key":"193_CR26","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1161\/CIRCULATIONAHA.107.739938","volume":"117","author":"K Ban","year":"2008","unstructured":"Ban K, Noyan-Ashraf MH, Hoefer J, Bolz S-S, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation. 2008;117:2340\u201350.","journal-title":"Circulation."},{"key":"193_CR27","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.regpep.2007.10.001","volume":"146","author":"DP Sonne","year":"2008","unstructured":"Sonne DP, Engstr\u00f8m T, Treiman M. Protective effects of GLP-1 analogues exendin-4 and GLP-1 (9\u201336) amide against ischemia-reperfusion injury in rat heart. Regul Pept. 2008;146:243\u20139.","journal-title":"Regul Pept."},{"key":"193_CR28","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1161\/CIRCULATIONAHA.112.091215","volume":"127","author":"MH Noyan-Ashraf","year":"2013","unstructured":"Noyan-Ashraf MH, Shikatani EA, Schuiki I, Mukovozov I, Wu J, Li RK, et al. A glucagon-like peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity. Circulation. 2013;127:74\u201385.","journal-title":"Circulation."},{"key":"193_CR29","doi-asserted-by":"publisher","first-page":"975","DOI":"10.2337\/db08-1193","volume":"58","author":"M Noyan-Ashraf","year":"2009","unstructured":"Noyan-Ashraf M, Momen M, Ban K, Al-Muktafi S, Zhou Y, Riazi AM, et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes. 2009;58:975\u201383.","journal-title":"Diabetes."},{"key":"193_CR30","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.jacc.2008.10.033","volume":"53","author":"L Timmers","year":"2009","unstructured":"Timmers L, Henriques JPS, De Kleijn DPV, Devries JH, Kemperman H, Steendijk P, et al. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol. 2009;53:501\u201310.","journal-title":"J Am Coll Cardiol."},{"key":"193_CR31","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1210\/en.2003-0007","volume":"144","author":"R Gros","year":"2003","unstructured":"Gros R, You X, Baggio L, Golam Kabir M, Sadi A, Mungrue I. Cardiac function in mice lacking the glucagon-like peptide-1 receptor. Endocrinology. 2003;144:2242\u201352.","journal-title":"Endocrinology."},{"key":"193_CR32","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/S0196-9781(03)00108-6","volume":"24","author":"M Kavianipour","year":"2003","unstructured":"Kavianipour M, Ehlers MR, Malmberg K, Ronquist G, Ryden L, Wikstrom G, et al. Glucagon-like peptide-1 (7\u201336) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium. Peptides. 2003;24:569\u201378.","journal-title":"Peptides."},{"key":"193_CR33","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1124\/jpet.106.100982","volume":"317","author":"T Zhao","year":"2006","unstructured":"Zhao T, Parikh P, Bhashyam S. Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J Pharmacol Exp Ther. 2006;317:1106\u201313.","journal-title":"J Pharmacol Exp Ther."},{"key":"193_CR34","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1124\/jpet.104.073890","volume":"312","author":"L Nikolaidis","year":"2005","unstructured":"Nikolaidis L, Doverspike A, Hentosz T. Glucagon-like peptide-1 limits myocardial stunning following brief coronary occlusion and reperfusion in conscious canines. J Pharmacol Exp Ther. 2005;312:303\u20138.","journal-title":"J Pharmacol Exp Ther."},{"key":"193_CR35","doi-asserted-by":"publisher","first-page":"H2401","DOI":"10.1152\/ajpheart.00347.2005","volume":"289","author":"LA Nikolaidis","year":"2005","unstructured":"Nikolaidis LA, Elahi D, Shen Y-T, Shannon RP. Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol. 2005;289:H2401\u20138.","journal-title":"Am J Physiol Heart Circ Physiol."},{"key":"193_CR36","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1210\/en.2009-1197","volume":"151","author":"K Ban","year":"2010","unstructured":"Ban K, Kim K-H, Cho C-K, Sauv\u00e9 M, Diamandis EP, Backx PH, et al. Glucagon-like peptide (GLP)-1 (9\u201336) amide-mediated cytoprotection is blocked by exendin(9\u201339) yet does not require the known GLP-1 receptor. Endocrinology. 2010;151:1520\u201331.","journal-title":"Endocrinology."},{"key":"193_CR37","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1161\/01.CIR.0000120505.91348.58","volume":"109","author":"LA Nikolaidis","year":"2004","unstructured":"Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, Elahi D, et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation. 2004;109:962\u20135.","journal-title":"Circulation."},{"key":"193_CR38","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.cardfail.2006.08.211","volume":"12","author":"GG Sokos","year":"2006","unstructured":"Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail. 2006;12:694\u20139.","journal-title":"J Card Fail."},{"key":"193_CR39","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.amjcard.2007.05.022","volume":"100","author":"GG Sokos","year":"2007","unstructured":"Sokos GG, Bolukoglu H, German J, Hentosz T, Magovern GJ, Maher TD, et al. Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. Am J Cardiol. 2007;100:824\u20139.","journal-title":"Am J Cardiol."},{"key":"193_CR40","doi-asserted-by":"publisher","first-page":"H1096","DOI":"10.1152\/ajpheart.00930.2009","volume":"298","author":"M Halbirk","year":"2010","unstructured":"Halbirk M, N\u00f8rrelund H, M\u00f8ller N, Holst JJ, Schmitz O, Nielsen R, et al. Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure. Am J Physiol Heart Circ Physiol. 2010;298:H1096\u2013102.","journal-title":"Am J Physiol Heart Circ Physiol."},{"key":"193_CR41","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1161\/CIRCIMAGING.109.899377","volume":"3","author":"PA Read","year":"2010","unstructured":"Read PA, Khan FZ, Heck PM, Hoole SP, Dutka DP. DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease. Circ Cardiovasc Imaging. 2010;3:195\u2013201.","journal-title":"Circ Cardiovasc Imaging."},{"key":"193_CR42","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1161\/CIRCINTERVENTIONS.110.960476","volume":"4","author":"PA Read","year":"2011","unstructured":"Read PA, Hoole SP, White PA, Khan FZ, O'Sullivan M, West NE, et al. A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans. Circ Cardiovasc Interv. 2011;4:266\u201372.","journal-title":"Circ Cardiovasc Interv."},{"key":"193_CR43","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1136\/hrt.2010.219345","volume":"98","author":"PA Read","year":"2012","unstructured":"Read PA, Khan FZ, Dutka DP. Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease. Heart. 2012;98:408\u201313.","journal-title":"Heart."},{"key":"193_CR44","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1093\/eurheartj\/ehr309","volume":"33","author":"J L\u00f8nborg","year":"2012","unstructured":"L\u00f8nborg J, Vejlstrup N, Kelb\u00e6k H, B\u00f8tker HE, Kim WY, Mathiasen AB, et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J. 2012;33:1491\u20139.","journal-title":"Eur Heart J."},{"key":"193_CR45","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1161\/CIRCIMAGING.113.000785","volume":"7","author":"LM McCormick","year":"2014","unstructured":"McCormick LM, Kydd AC, Read PA, Ring LS, Bond SJ, Hoole SP, et al. Chronic dipeptidyl peptidase-4 inhibition with sitagliptin is associated with sustained protection against ischemic left ventricular dysfunction in a pilot study of patients with type 2 diabetes mellitus and coronary artery disease. Circ Cardiovasc Imaging. 2014;7:274\u201381.","journal-title":"Circ Cardiovasc Imaging."},{"key":"193_CR46","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/S0140-6736(09)61375-1","volume":"374","author":"A Astrup","year":"2009","unstructured":"Astrup A, R\u00f6ssner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M, et al. NN8022-1807 Study Group. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009;374:1606\u201316.","journal-title":"Lancet."},{"key":"193_CR47","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1136\/heart.88.6.604","volume":"88","author":"RJ Edwards","year":"2002","unstructured":"Edwards RJ, Redwood SR, Lambiase PD, Tomset E, Rakhit RD, Marber MS. Antiarrhythmic and anti-ischaemic effects of angina in patients with and without coronary collaterals. Heart. 2002;88:604\u201310.","journal-title":"Heart."},{"key":"193_CR48","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1093\/eurheartj\/ehi082","volume":"26","author":"RJ Edwards","year":"2005","unstructured":"Edwards RJ, Redwood SR, Lambiase PD, Marber MS. The effect of an angiotensin-converting enzyme inhibitor and a K+(ATP) channel opener on warm up angina. Eur Heart J. 2005;26:598\u2013606.","journal-title":"Eur Heart J."},{"key":"193_CR49","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/S0735-1097(03)00055-X","volume":"41","author":"PD Lambiase","year":"2003","unstructured":"Lambiase PD, Edwards RJ, Cusack MR, Bucknall CA, Redwood SR, Marber MS. Exercise-induced ischemia initiates the second window of protection in humans independent of collateral recruitment. J Am Coll Cardiol. 2003;41:1174\u201382.","journal-title":"J Am Coll Cardiol."},{"key":"193_CR50","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1161\/CIRCULATIONAHA.112.094292","volume":"126","author":"TPE Lockie","year":"2012","unstructured":"Lockie TPE, Rolandi MC, Guilcher A, Perera D, De Silva K, Williams R, et al. Synergistic adaptations to exercise in the systemic and coronary circulations that underlie the warm-up angina phenomenon. Circulation. 2012;126:2565\u201374.","journal-title":"Circulation."},{"key":"193_CR51","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1136\/heartjnl-2013-304187","volume":"100","author":"RP Williams","year":"2014","unstructured":"Williams RP, Manou-Stathopoulou V, Redwood SR, Marber MS. \u201cWarm-up Angina\u201d: harnessing the benefits of exercise and myocardial ischaemia. Heart. 2014;100:106\u201314.","journal-title":"Heart."},{"key":"193_CR52","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1093\/eurheartj\/ehm187","volume":"28","author":"M Saha","year":"2007","unstructured":"Saha M, Redwood SR, Marber MS. Exercise training with ischaemia: is warming up the key? Eur Heart J. 2007;28:1543\u20134.","journal-title":"Eur Heart J."},{"key":"193_CR53","first-page":"276","volume":"109","author":"S Wellek","year":"2012","unstructured":"Wellek S, Blettner M. Vom richtigen Umgang mit dem Crossover-Design in klinischen Studien: Teil 18 der Serie zur Bewertung wissenschaftlicher Publikationen. Dtsch Arztebl Int. 2012;109:276\u201381.","journal-title":"Dtsch Arztebl Int."}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12933-015-0193-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-015-0193-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-015-0193-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-015-0193-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T08:25:20Z","timestamp":1630571120000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-015-0193-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,19]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["193"],"URL":"https:\/\/doi.org\/10.1186\/s12933-015-0193-4","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,19]]},"assertion":[{"value":"26 January 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"27"}}